Skip to content. | Skip to navigation

News
>
Establishing a Successful Clinical Fill & Finish Manufacturing Site for Biologics

Establishing a Successful Clinical Fill & Finish Manufacturing Site for Biologics

Medium: Drug Development and Delivery
Author: Dr. Susanne Resatz, President of Vetter Development Services USA, Inc.

Small biotech companies are faced with a series of complex issues when it comes to early drug development. These include a lack of experience and infrastructure, a lack of financial resources, and limited availability of valuable API. Can the right partner support the specific needs of the small biotech? What skills and infrastructure must a CDMO possess to meet their specific needs? How can a CDMO help with financial resource timelines and scheduling?

In the world of manufacturing for biologics, particularly for the small biotech company, having the right site to support them is crucial. It is now 5 years since Vetter opened its clinical fill & finish facility in Chicago, successfully serving its customer base with their needs in mind. What are the skills and infrastructure that Vetter has employed to help meet the needs of the small biotech? What has been their overall approach to layout and material flow? How has the Chicago site been performing over the last 5 years? Dr. Susanne Resatz, President of Vetter Development Services USA, Inc. offers her insight to these questions and more in Issue xx of Drug Development and Delivery. 


EXECUTIVE INTERVIEW - Vetter: Establishing a Successful Clinical Fill & Finish Manufacturing Site for Biologics

 

More news